T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2B |
| 2 |
Sea Limited
SE
|
+$1.34B |
| 3 |
Morgan Stanley
MS
|
+$1.23B |
| 4 |
Incyte
INCY
|
+$1.05B |
| 5 |
Ross Stores
ROST
|
+$968M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.05B |
| 2 |
VMW
VMware, Inc
VMW
|
+$1.5B |
| 3 |
Visa
V
|
+$1.16B |
| 4 |
JPMorgan Chase
JPM
|
+$1.13B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.01% |
| 2 | Healthcare | 17.6% |
| 3 | Consumer Discretionary | 14.37% |
| 4 | Financials | 11.89% |
| 5 | Communication Services | 10.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1176
Eastman Chemical
EMN
$8.29B
| $17.5M | ﹤0.01% |
251,660
-19,809
| -7% | -$1.25M |
|
|
CATM
1177
DELISTED
Cardtronics plc Class A Ordinary Shares (UK)
CATM
| $17.5M | ﹤0.01% |
729,531
-92,786
| -11% | -$2.08M |
|
1178
Huntington Bancshares
HBAN
$36.1B
| $17.5M | ﹤0.01% |
1,934,885
-142,850
| -7% | -$1.26M |
|
|
MRSN
1179
DELISTED
Mersana Therapeutics
MRSN
| $17.4M | ﹤0.01% |
+29,809
| New | +$10.2M |
|
|
TECX
1180
Tectonic Therapeutic
TECX
$720M
| $17.3M | ﹤0.01% |
82,663
+8,118
| +11% | +$1.67M |
|
1181
Western Union
WU
$2.34B
| $17.1M | ﹤0.01% |
792,268
-65,759
| -8% | -$1.34M |
|
1182
Diageo
DEO
$52.8B
| $17.1M | ﹤0.01% |
127,146
+2,222
| +2% | +$305K |
|
1183
Pultegroup
PHM
$24.6B
| $16.9M | ﹤0.01% |
497,423
-25,347
| -5% | -$761K |
|
|
FOLD
1184
DELISTED
Amicus Therapeutics
FOLD
| $16.9M | ﹤0.01% |
1,121,253
+171,408
| +18% | +$2.09M |
|
1185
Pinnacle West Capital
PNW
$12.2B
| $16.6M | ﹤0.01% |
226,026
-16,061
| -7% | -$1.21M |
|
1186
Supernus Pharmaceuticals
SUPN
$2.78B
| $16.5M | ﹤0.01% |
694,952
+7,633
| +1% | +$169K |
|
1187
Timken Company
TKR
$9.03B
| $16.4M | ﹤0.01% |
360,876
+142,462
| +65% | +$5.63M |
|
1188
Ameris Bancorp
ABCB
$5.94B
| $16.4M | ﹤0.01% |
694,285
-153,444
| -18% | -$3.6M |
|
1189
Madrigal Pharmaceuticals
MDGL
$12.4B
| $16.3M | ﹤0.01% |
143,975
+97,257
| +208% | +$9.56M |
|
|
AXNX
1190
DELISTED
Axonics, Inc. Common Stock
AXNX
| $16.2M | ﹤0.01% |
+462,111
| New | +$15.9M |
|
1191
Uber
UBER
$155B
| $16.2M | ﹤0.01% |
521,337
-2,411,011
| -82% | -$75.1M |
|
1192
Iron Mountain
IRM
$37B
| $16.2M | ﹤0.01% |
619,837
-65,830
| -10% | -$1.66M |
|
1193
Huron Consulting
HURN
$2.39B
| $16.2M | ﹤0.01% |
365,392
-84,692
| -19% | -$3.82M |
|
1194
Viatris
VTRS
$18.5B
| $16.2M | ﹤0.01% |
1,005,409
-84,297
| -8% | -$1.37M |
|
1195
Walker & Dunlop
WD
$1.45B
| $16.1M | ﹤0.01% |
317,491
+297,877
| +1,519% | +$12.2M |
|
|
CDR
1196
DELISTED
Cedar Realty Trust, Inc
CDR
| $15.9M | ﹤0.01% |
2,435,215
+316
| +0% | +$1.94K |
|
1197
Everest Group
EG
$13.9B
| $15.9M | ﹤0.01% |
77,095
-5,978
| -7% | -$1.16M |
|
1198
Assembly Biosciences
ASMB
$536M
| $15.9M | ﹤0.01% |
56,761
-4,665
| -8% | -$1.09M |
|
|
NVTA
1199
DELISTED
Invitae Corporation
NVTA
| $15.7M | ﹤0.01% |
516,923
+501,639
| +3,282% | +$8.75M |
|
1200
Southern First Bancshares
SFST
$607M
| $15.6M | ﹤0.01% |
563,362
+16,609
| +3% | +$451K |
|
Similar funds
T. Rowe Price Associates's Q2 2020 Portfolio in Review
As of Q2 2020, T. Rowe Price Associates held 2,591 positions worth $795B, up 26% from $632B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
T. Rowe Price Associates's Q2 2020 filing shows 79 new, 1,096 increased, 1,255 reduced and 100 closed positions. Its largest new stake was Vroom Inc: 200,362 shares worth $797M. The largest sale was Boeing, an estimated $2.05B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2020 buy was Vroom Inc: 200,362 shares worth $797M.
- T. Rowe Price Associates added most to Microsoft in Q2 2020, an estimated $2B increase.
- T. Rowe Price Associates's biggest Q2 2020 reduction was Boeing, cutting an estimated $2.05B.
- T. Rowe Price Associates fully exited Raytheon Company in Q2 2020, selling an estimated $1.01B.
- T. Rowe Price Associates's ten largest holdings make up 25% of its $795B portfolio in Q2 2020.
- T. Rowe Price Associates opened 79 new positions and closed 100 in Q2 2020.
- T. Rowe Price Associates's portfolio value rose 26% quarter-over-quarter to $795B.
Based on T. Rowe Price Associates's 13F filing for Q2 2020, filed 14 Aug 2020.